On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics ( NTLA ) ...

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...

Intellia Therapeutics has a promising candidate about to enter late-stage testing. The company has a couple of exciting earlier-stage programs, too. Despite recent progress, the biotech remains risky.

Many investors were skeptical of biotechs specializing in gene editing three years ago. Though some had made clinical progress, few had launched any product. Since then, there have been more clinical ...

Wall Street analysts have high hopes for Intellia Therapeutics stock. The company's late-stage pipeline programs are shaping up nicely. Upcoming data readouts will need to be very impressive to hit ...

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 22,800 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three ...

On Thursday, Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of late-stage programs for NTLA-2002 and nex-z. These therapies target ...

Thursday was hardly a good day to be a shareholder of Intellia Therapeutics (NASDAQ: NTLA). After the biotech delivered some news from the lab and witnessed one analyst's negative reaction to it, the ...

Intellia Therapeutics, Inc. enrollment completion for the phase 2 study using NTLA-2002 for the treatment of hereditary angioedema is expected in Q4 2023; Results expected in 2024. Pending positive ...

Wall Street analysts are quite bullish about Intellia Therapeutics (NASDAQ: NTLA) stock. On average, they're estimating that it'll rise by around 157% within the next 12 months. In the context of the ...